Lentivirus-mediated estrogen receptor a overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice

International Journal of Molecular Medicine

Volumn 31, Issue 5, 2013, Pages 1209-1221

  Hu, Xiao ^a,b   Qin, Xinyue ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Estrogen; Estrogen receptor a; Inflammatory response; Multiple sclerosis; Recombinant lentivirus

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GAMMA INTERFERON; GELATINASE B; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; MESSENGER RNA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APPETITE DISORDER; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CELL CULTURE; CELL INFILTRATION; CELL INVASION; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN THERAPY; FEMALE; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LATERAL BRAIN VENTRICLE; LENTIVIRINAE; LENTIVIRUS INFECTION; LYMPHOCYTE; MOUSE; MULTIPLE SCLEROSIS; MYELINATION; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; BODY WEIGHT; BRAIN; CENTRAL NERVOUS SYSTEM; CYTOKINES; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ESTROGEN RECEPTOR ALPHA; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LENTIVIRUS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MYELIN BASIC PROTEIN; NERVE FIBERS; RECOMBINATION, GENETIC; RNA, MESSENGER; SPINAL CORD; TRANSFECTION;

EID: 84876137264     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1306     Document Type: Article

References (69)

1. Ouallet J, Baumann N, Marie Y and Villarroya H: Fas system up-regulation in experimental autoimmune encephalomyelitis. J Neurol Sci 170: 96-104, 1999.
2. Barac-Latas V, Muhvic D and Radosevic-Stabic B: The influence of pregnancy on development and course of chronic relapsing experimental autoimmune encephalomyelitis in rats: Implications for multiple sclerosis. Coll Antropol 34 (Suppl 1): 267-271, 2010.
3. Runmarker B and Andersen O: Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118: 253-261, 1995.
4. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P and Moreau T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339: 285-291, 1998.
5. Niino M, Hirotani M, Fukazawa T, Kikuchi S and Sasaki H: Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem 9: 87-94, 2009.
6. Sicotte NL, Liva SM, Klutch R, et al: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52: 421-428, 2002.
7. Soldan SS, Alvarez Retuerto AI, Sicotte NL and Voskuhl RR: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 171: 6267-6274, 2003.
8. Lelu K, Laffont S, Delpy L, et al: Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol 187: 2386-2393, 2011.
9. Wang C, Dehghani B, Li Y, et al: Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 182: 3294-3303, 2009.
10. Bodhankar S, Wang C, Vandenbark AA and Offner H: Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol 41: 1165-1175, 2011.
11. Subramanian S, Yates M, Vandenbark AA and Offner H: Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology 132: 340-347, 2011.
12. Gold SM and Voskuhl RR: Estrogen treatment in multiple sclerosis. J Neurol Sci 286: 99-103, 2009.
13. MacKenzie-Graham AJ, Rinek GA, Avedisian A, et al: Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res 90: 1310-1323, 2012.
14. Ziehn MO, Avedisian AA, Dervin SM, O'Dell TJ and Voskuhl RR: Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest 92: 1234-1245, 2012.
15. Giraud SN, Caron CM, Pham-Dinh D, Kitabgi P and Nicot AB: Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc Natl Acad Sci USA 107: 8416-8421, 2010.
16. Bodhankar S and Offner H: Gpr30 forms an integral part of E2-protective pathway in experimental autoimmune encephalomyelitis. Immunol Endocr Metab Agents Med Chem 11: 262-274, 2011.
17. Matejuk A, Bakke AC, Hopke C, Dwyer J, Vandenbark AA and Offner H: Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res 77: 119-126, 2004.
18. Tiwari-Woodruff S and Voskuhl RR: Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neurol Sci 286: 81-85, 2009.
19. Du S, Sandoval F, Trinh P, Umeda E and Voskuhl R: Estrogen receptor-beta ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease. Eur J Immunol 41: 140-150, 2011.
20. Blasko E, Haskell CA, Leung S, et al: Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 214: 67-77, 2009.
21. Subramanian S, Miller LM, Grafe MR, Vandenbark AA and Offner H: Contribution of GPR30 for 1,25 dihydroxyvitamin D(3) protection in EAE. Metab Brain Dis 27: 29-35, 2012.
22. Lelu K, Delpy L, Robert V, et al: Endogenous estrogens, through estrogen receptor alpha, constrain autoimmune inflammation in female mice by limiting CD4+ T-cell homing into the CNS. Eur J Immunol 40: 3489-3498, 2010.
23. Gold SM, Sasidhar MV, Morales LB, et al: Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest 89: 1076-1083, 2009.
24. Spence RD, Hamby ME, Umeda E, et al: Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci USA 108: 8867-8872, 2011.
25. Wong LF, Goodhead L, Prat C, Mitrophanous KA, Kingsman SM and Mazarakis ND: Lentivirus-mediated gene transfer to the central nervous system: Therapeutic and research applications. Hum Gene Ther 17: 1-9, 2006.
26. Foster TC, Rani A, Kumar A, Cui L and Semple-Rowland SL: Viral vector-mediated delivery of estrogen receptor-alpha to the hippocampus improves spatial learning in estrogen receptor-alpha knockout mice. Mol Ther 16: 1587-1593, 2008.
27. Brewer GJ, Torricelli JR, Evege EK and Price PJ: Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurol Sci 35: 567-576, 1993.
28. Hu X, Lei L, Yuan J, Xing W, W JY and Qin X: Construction of recombinant lentivirus carrying mouse estrogen receptor α and identification in infected neurons. Acad J Sec Mil Med Univ 32: 160-166, 2011.
29. Tiwari-Woodruff S, Morales LB, Lee R and Voskuhl RR: Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci USA 104: 14813-14818, 2007.
30. Tapia-Gonzalez S, Carrero P, Pernia O, Garcia-Segura LM and Diz-Chaves Y: Selective Er modulators reduce microglia reactivity in vivo after peripheral inflammation: Potential role of microglial ERs. J Endocrinol 198: 219-230, 2008.
31. Legge KL, Min B, Bell JJ, et al: Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J Exp Med 191: 2039-2052, 2000.
32. Murphy AC, Lalor SJ, Lynch MA and Mills KH: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 24: 641-651, 2010.
33. Jacobs EC: Genetic alterations in the mouse myelin basic proteins result in a range of dysmyelinating disorders. J Neurol Sci 228: 195-197, 2005.
34. Molineaux SM, Engh H, De Ferra F, Hudson L and Lazzarini RA: Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. Proc Natl Acad Sci USA 83: 7542-7546, 1986.
35. Fainardi E, Castellazzi M, Bellini T, et al: Cerebrospinal fluid and serum levels and intrathecal production of active MMP-9 as markers of disease activity in patients with multiple sclerosis. Mult Scler 12: 294-301, 2006.
36. Kurzepa J, Bartosik-Psujek H, Suchozebrska-Jesionek D, Rejdak K, Stryjecka-Zimmer M and Stelmasiak Z: Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Neurol Neurochir Pol 39: 63-67, 2005 (In Polish).
37. Rubinson DA, Dillon CP, Kwiatkowski AV, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401-406, 2003.
38. Trobridge G and Russell DW: Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 78: 2327-2335, 2004.
39. Yip PK, Wong LF, Pattinson D, et al: Lentiviral vector expressing retinoic acid receptor beta2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cord. Hum Mol Genet 15: 3107-3118, 2006.
40. Ambrosino C, Tarallo R, Bamundo A, et al: Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei. Mol Cell Proteomics 9: 1352-1367, 2010.
41. Vigna E and Naldini L: Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2: 308-316, 2000.
42. Bruck W: The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 252 (Suppl 5): V3-v9, 2005.
43. Liu HY, Buenafe AC, Matejuk A, et al: Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurol Sci 70: 238-248, 2002.
44. Baumann N and Pham-Dinh D: Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 81: 871-927, 2001.
45. Daigle JL, Hong JH, Chiang CS and McBride WH: The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Res 61: 8859-8865, 2001.
46. Griffiths I, Klugmann M, Anderson T, et al: Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280: 1610-1613, 1998.
47. De Rosbo NK and Bernard CC: Multiple sclerosis brain immunoglobulins stimulate myelin basic protein degradation in human myelin: A new cause of demyelination. J Neurochem 53: 513-518, 1989.
48. Einstein ER, Csejtey J, Dalal KB, Adams CW, Bayliss OB and Hallpike JF: Proteolytic activity and basic protein loss in and around multiple sclerosis plaques: Combined biochemical and histochemical observations. J Neurochem 19: 653-662, 1972.
49. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS and Fares C: Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 35: 503-542, 2004.
50. Crawford DK, Mangiardi M, Song B, et al: Oestrogen receptor beta ligand: A novel treatment to enhance endogenous functional remyelination. Brain 133: 2999-3016, 2010.
51. Garay L, Gonzalez Deniselle MC, Gierman L, et al: Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation 15: 76-83, 2008.
52. Sarkaki A, Amani R, Badavi M, et al: Pre-treatment effect of different doses of soy isoflavones on spatial learning and memory in an ovariectomized animal model of Alzheimer's disease. Pak J Biol Sci 11: 1114-1119, 2008.
53. Sheldahl LC, Marriott LK, Bryant DM, Shapiro RA and Dorsa DM: Neuroprotective effects of estrogen and selective estrogen receptor modulators begin at the plasma membrane. Minerva Endocrinol 32: 87-94, 2007.
54. Riggs BL and Hartmann LC: Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629, 2003.
55. Chitnis T and Khoury SJ: Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res 28: 223-239, 2003.
56. McGeachy MJ and Anderton SM: Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 32: 81-84, 2005.
57. Suryani S and Sutton I: An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol 183: 96-103, 2007.
58. Butti E, Bergami A, Recchia A, et al: IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther 15: 504-515, 2008.
59. Bebo BF Jr, Dehghani B, Foster S, Kurniawan A, Lopez FJ and Sherman LS: Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 57: 777-790, 2009.
60. Juedes AE, Hjelmstrom P, Bergman CM, Neild AL and Ruddle NH: Kinetics and cellular origin of cytokines in the central nervous system: Insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 164: 419-426, 2000.
61. Monteiro de Castro G, Eduarda Zanin M, Ventura-Oliveira D, Aparecida Vilella C, Ashimine R and De Lima Zollner R: Th1 and Th2 cytokine immunomodulation by gangliosides in experimental autoimmune encephalomyelitis. Cytokine 26: 155-163, 2004.
62. Abraham M, Shapiro S, Karni A, Weiner HL and Miller A: Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 163: 157-164, 2005.
63. Correale J and Bassani Molinas Mde L: Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 140: 198-209, 2003.
64. Illes Z, Safrany E, Peterfalvi A, et al: 3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett 431: 36-38, 2008.
65. Harrington LE, Hatton RD, Mangan PR, et al: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132, 2005.
66. Kawanokuchi J, Shimizu K, Nitta A, et al: Production and functions of IL-17 in microglia. J Neuroimmunol 194: 54-61, 2008.
67. Kolls JK and Linden A: Interleukin-17 family members and inflammation. Immunity 21: 467-476, 2004.
68. Tian AY, Zhang RW, Shi XG and Yu HM: Alteration of T helper cell subsets in the optic nerve of experimental autoimmune encephalomyelitis. Int J Mol Med 25: 869-874, 2010.
69. Uyttenhove C, Sommereyns C, Theate I, Michiels T and van Snick J: Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann NY Acad Sci 1110: 330-336, 2007.